By Lisa Kerner
Charlotte, N.C., June 16 - VLST Corp. said it completed a $55 million round of series B financing.
The financing, provided in three tranches, will be used to bring the company's lead product through a phase 2 proof-of-concept trial and to prepare for Investigational New Drug filings.
Texas Pacific Group Ventures led the financing round, joined by existing investors MPM Capital, ARCH Venture Partners, OVP Venture Partners and Amgen Ventures. New investors include MedImmune Ventures Inc. and WRF Capital., the venture investment arm of the Washington Research Foundation.
Seattle-based VLST is a privately held biotechnology company focused on therapeutics for the treatment of inflammatory and autoimmune diseases.
| Issuer: | VLST Corp.
|
| Issue: | Series B financing
|
| Amount: | $55 million
|
| Investors: | Texas Pacific Group Ventures (lead), MPM Capital, ARCH Venture Partners, OVP Venture Partners, Amgen Ventures, MedImmune Ventures Inc., WRF Capital.
|
| Announcement date: | June 16
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
